Last reviewed · How we verify
Placebo B (After CP)
Placebo B is an inert control substance with no active pharmacological mechanism.
At a glance
| Generic name | Placebo B (After CP) |
|---|---|
| Sponsor | Janssen Pharmaceutical K.K. |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
As a placebo, this agent contains no active pharmaceutical ingredient and produces no direct molecular or biological effect. It is used as a control comparator in clinical trials to assess the efficacy and safety of active investigational drugs by isolating the true drug effect from placebo response.
Approved indications
Common side effects
Key clinical trials
- Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (PHASE3)
- Axatilimab Plus Standard of Care Therapy for the Prevention of Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Cancer, ABRAXAS Trial (PHASE2)
- Study to Evaluate Efficacy of OLX10010 in Reducing Recurrence of Hypertrophic Scarring After Scar Revision Surgery (PHASE2)
- Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer (PHASE2)
- An Efficacy and Safety Study of Ustekinumab (CNTO 1275) in Participants With Plaque Psoriasis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo B (After CP) CI brief — competitive landscape report
- Placebo B (After CP) updates RSS · CI watch RSS
- Janssen Pharmaceutical K.K. portfolio CI